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An etoposide-resistant lung cancer subline overexpresses the multidrug
resistance-associated protein
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Summarv We have characterised an etoposide-resistant subline of the small-cell lung cancer cell line.
UMCC-1. derinved at our centre. Subline UMCC-1 VP was developed bY culturing the parent hne in increasing
concentrations of etoposide over 16 months. UMCC-1 VP is 20-fold resistant to etoposide by MTT assays.
relative to the parent line. and is cross-resistant to doxorubicin. vincristine and actinomycin D. but not to
taxol. cisplatin. melphalan. thiotepa or idarubicin. Topoisomerase II immunoblotting demonstrates a 500o
reduction of the protein in the resistant subline. The UMCC-1 VP subline demonstrates a marked decrease in
the accumulation of [3HIetoposide relative to the parent line. as well as a modest reduction in the accumula-
tion of daunorubicin. Reverse transcription-polymerase chain reaction assays demonstrate no detectable mdrl
expression but marked expression of the multidrug resistance-associated protein (MRP) gene in the resistant
subline. Northern blotting with an MRP cDNA probe confirms marked overexpression of the MRP gene only
in the UMCC-1 VP subline. Western blotting with antisera against MRP peptide confirms a 195 kDa protein
band in the UMCC-1 VP subline. Southern blotting experiments demonstrate a 10-fold amplification of the
MRP gene in the resistant subline. Depletion of glutathione with buthionine sulphoximine sensitised UMCC-1
VP cells to daunorubicin and etoposide. Our studies indicate that MRP gene expression may be induced bv
etoposide and may lead to reduced accumulation of the drug.
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In most patients with small-cell lung cancer (SCLC) tumours
will respond initially to combination chemotherapy followed
bv a recurrence of cancer which is refractory to multiple
cytotoxic agents (Harper et al.. 1982). Multidrug-resistant
SCLC tumours. like other bronchial carcinomas. have
generally not been found to have overexpression of P-
glycoprotein. a transmembrane protein which in other human
tumours has been demonstrated to produce resistance by
acting as an energy-dependent drug export transporter
(Goldstein et al.. 1989: Lai et al. 1989). The pattern of
anti-cancer drug resistance seen in SCLC cells in vitro is often
different from that of P-glycoprotein-mediated multidrug
resistance (Giaccone et al.. 1992: Jensen et al.. 1993). Fur-
thermore. multidrug resistance in cultured lung cancer cells is
poorly reversed by chemosensitisers that are effective in cells
which overexpress P-glycoprotein (Cole et al.. 1989). There
has been considerable recent interest in discovering the
mechanisms underlying non-P-glycoprotein-mediated multi-
drug resistance in human lung cancer cells (Bergh et al..
1990: Doyle. 1993).
The gene for a novel drug transporter. termed the multi-
drug resistance-associated protein (MRP), was recently found
to be amplified and overexpressed in a doxorubicin-selected
SCLC cell line which is multiply drug resistant but does not
overexpress P-glvcoprotein (Cole et al.. 1992). Several other
doxorubicin-selected cancer cell lines have subsequently been
found to have overexpression of the MRP gene (Slovak et
al.. 1993: Barrand et al.. 1994). A full-length cDNA of MRP
has been cloned, and two independent transfection experi-
ments have demonstrated that cells transfected with MRP
expression vectors demonstrate resistance to doxorubicin.
etoposide and vincristine proportional to the levels of the
190 kDa membrane protein expressed by the MRP gene
(Grant et al.. 1994a; Kruh et al.. 1994). Overexpression of
MRP has recently been found to result in increased ATP-
dependent glutathione S-conjugate transport (Jedlitschky et
al., 1994: Muller et al.. 1994). Increased expression of MRP
has been found in relapsed acute leukaemia blasts, suggesting
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that MRP may contribute to clinical drug resistance in
human cancer (Schneider et al.. 1995).
Etoposide is one of the most clinically important drugs in
the frontline treatment of SCLC tumours (Cavalli et al..
1978). The activity of etoposide results from a specific
interaction of the drug with the nuclear enzyme topoiso-
merase II (Yang et al.. 1985). This enzyme has the ability to
alter the topological state of DNA and has a critical role in
DNA replication. chromosomal segregation and RNA trans-
cription (Liu. 1989: Osheroff et al.. 1991). Topoisomerase II
binds covalently to DNA and cleaves both strands, produc-
ing an intermediate termed the 'cleavable complex'. Drugs
such as etoposide stabilise the cleavable complexes, and the
double-stranded DNA breaks lead to cell death by. as yet.
poorly defined mechanisms (Kaufmann. 1989). Drug resis-
tance to topoisomerase TI-directed agents can result from any
mechanism that decreases the number of stabilised cleaved
complexes. Studies of lung cancer cell lines with selective
resistance to topoisomerase 1I-directed agents have detected
both qualitative and quantitative alterations of the enzyme.
While epipodophyllotoxin derivatives are usually included
among the drugs recognised in the classic multidrug resis-
tance phenotype. efflux studies indicate that these drugs are
relatively poor substrates for P-glycoprotein (Sehested et al..
1992).
As models to study etoposide resistance in SCLC. we have
derived the UMCC-l VP and NCI-H1514 VP sublines bv
stepwise selection of the parent lines in etoposide. The pur-
pose of our study was to characterise the drug resistance
phenotype of the resistant sublines by determining their
cross-resistance pattern. to investigate alterations in the
target enzyme topoisomerase II and to examine changes in
cellular accumulation of etoposide as well as the expression
of membrane proteins implicated in the efflux of cytotoxic
drugs.
Materials and methods
Vaterials
RPMI-1640 medium and fetal bovine serum were obtained
from Gibco (Grand Island. NY. USA). [x-3rP]dCTP wasEki)posode rsnctme wfth MRP over xpresson %e LA Doyle et a
obtained from Amersham (Arlington Heights. IL. USA) and
['H]etoposide (specific activity. 900 mCi mmol -) was ob-
tained from Morovek Laboratories (Brea. CA. USA).
Etoposide and taxol were obtained from Bristol-Mvers-
Squibb (Syracuse. NY. USA). doxorubicin and idarubicin
from Adria Laboratories (Columbus. OH. USA). dauno-
rubicin from WNeth Laboratories (Philadelphia. PA. USA).
thiotepa from Lederle Laboratories (Pearl River. NY. USA).
and verapamil. buthionine sulphoximine (BSO). v-incristine.
cisplatin. melphalan and actinomycin D from Sigma (St
Louis. MO. USA). CN-closporin A was kindly supplied by
Sandoz (Basel. Swvitzerland). Polyclonal antisera against
topoisomerase II xxas a generous gift from Dr LF Liu
(UMDNJ Robert Wood Johnson Medical School. Pis-
catawav. NJ. USA).
Cell culture
The NCI-H1514 cell line was a generous gift from Dr A
Gazdar (Simmons Cancer Center. Dallas. TX. USA) and was
obtained from an extensive-stage SCLC patient before the
initiation of chemotherapy (Gazdar et al.. 1990). The
UMCC-1 cell line w-as established from the bone marrow of
a 64-year-old male patient w-ith extensive SCLC treated at
the University of Marnland Cancer Center. The marrow
w-as obtained after the patient had relapsed following
several different combinations of chemotherapy. including
carboplatinum. etoposide. cyclophosphamide. doxorubicin.
vinblastine. cisplatinum. methotrexate. v-incristine and cyc-
lohexylchloroethylnitrosourea (CCNU). The UMCC-1 cell
line has a colony morphology and cytogenetic abnormalities
characteristic of SCLC (Miura et al.. 1992)
The cell lines Awere maintained in RPMI-1640 medium
containinz 2rmn L-zlutamine and 10°00 fetal bovine serum
(Hyclone. Logan. UT. USA). Etoposide-resistant sublines of
NCI-H1514 and UMCC-l1 were selected by stepwise con-
tinuous exposure to increasing concentrations of etoposide.
starting at 0.05 AJi. Once the cells were adapted to a given
concentration of etoposide the cultures w-ere typically
changed to a 2-fold increased concentration of the drug.
Cells x-ere not exposed to mutagens before selection. Each
subline was subcloned by limiting dilution four times during
a 16 month period. The resistant subline of NCI-H1514 is
termed NCI-H1514 VP. and this subline was maintained con-
tinuously in 2 6iM etoposide. The resistant subline of UMCC-
1 is termed UMCC-1 VP. The UMCC-1 VP subline can
survive continuous exposure to 16Am etoposide for several
weeks. but w as chronically- maintained at 4 M etoposide.
Both resistant sublines were maintained in etoposide until
7-14 days before the initiation of the individual experiments
described. The leukaemia cell line HL-60. its doxorubicin-
resistant subline HL-60 Adr and its v-incristine-resistant sub-
line HL-60 Vinc were zenerous gifts from Dr M Center of
Kansas State Universitv (Marsh et al.. 1986: McGrath and
Center. 1987). The doxorubicin-resistant HL-60 AR subline
>-as a generous gift from Dr A Hindenberg at the Winthrop
Universitv School of Medicine (Bhalla et al.. 1985).
Chemosensitzivit!u testing
MTT (3-(4.5-dimethylthiazol-2-yl)X-1.5-dipeny ltetrazolium bro-
mide) assays A-ere performed with minor modifications of the
method of Mosmann (1983). Briefly. 10 000 cells of each line
were plated in 100 jil of medium in w-ells of 96-well microtitre
plates for 24h before the addition of drug. After overnight
incubation at 37C. appropnrate concentrations of drug u-ere
added to each A-ell. Drugs were made up in medium at five
times the desired final concentration. and 25 LLl of medium
contaimnig the drug stocks w-as added to each well. After a
72 h incubation at 37°C. 10pl of MTT (5 mg ml-' stock) was
added to each A-ell. Plates wxere then incubated for an addi-
tional 4 h at 37C. after which the medium wAas removed and
the remaining formazan cry stals solubilised in 100 Ll of
dimethylsulphoxide (DMSO). Plates were read on a Dynatek
model 740 plate reader with a reference w-avelength of
410 nm and a test wavelength of 490 nm. These data were
downloaded into SigmaPlot (Jandel Scientific. San Rafael.
CA. USA) for evaluation and graphing. The fold resistance is
expressed as a ratio of the ICio of the resistant cell line
relativ-e to that of the sensitiv-e cell line. Each drug w-as tested
in at least tw-o independent experiments. and w-ithin each
experiment determinations w-ere done in quadruplicate.
In sensitisation experiments. cells u-ere incubated w-ith
2 5 m cyclosporin A or 10Jm verapamil for 30 mn before
the addition of etoposide. Cellular depletion of glutathione.
in other experiments. Aas performed by the addition of
25-50Jm BSO to cells 24 h before the addition of
daunorubicin or etoposide.
Etoposide accumulation
Etoposide accumulation w-as quantitated as previously des-
cribed (Hamza et al.. 1987). A total of 4 x 10' cells was
plated into T-25 flasks. After incubation for 2 days at 37C
the cells were harvested. washed and resuspended in RPMI-
1640 medium with 10% fetal bovine serum (FBS). contairnng
0.5pCiml-' [3HJetoposide (900mCimmol-P) plus 10gm
unlabelled etoposide. Duplicate flasks were incubated for
various times from 0 to 90 min then placed on ice. The cells
were washed three times with cold phosphate-buffered saline
(PBS) and the cell pellet was lvophilised overnight. The dried
pellet was dissolved in 0.25 ml of 1 N sodium hydroxide for
4 h at room temperature. then neutralised with 0.25 ml of 1 N
hydrochloric acid. One-third of the reaction mixture was
used to determine protein concentration by the method of
Lowry et al. (1951). with albumin as a standard. and the rest
was processed for radioactivity-with scintillation counting.
Daunorubicin accumulation and retention
Approximately 1 x 10O cells of each line were plated into
T-25 flasks and incubated ov-ernight in complete medium.
The cells were exposed to 1 jg ml-' daunorubicin. and at the
indicated time points intracellular daunorubicin accumulation
w-as determined as previously described (Ross et al.. 1993).
Daunorubicin fluorescence assays were performed on a flow
cytometer (FACStar Plus. Becton Dickinson. San Jose. CA.
USA) using laser excitation of 488 nm and reading
fluorescence emission with the use of a 575-25 filter.
Logarithmic amplification of red fluorescence signals was
used throughout. Fluorescent beads (Propidium Iodide
Alignment Microbead Standards. Flow Cytometry Standards
Corporation. Research Triangle. NC. USA) Awere used to
ensure reproducibility of the fluorescence measurements.
Relative intracellular daunorubicin content for a particular
sample was obtained by dividing the channel number that
represented mean red fluorescence for that sample by 256
(the number of channels per log decade). then obtaining the
antilog of this value. Ten thousand cells were used for each
determination. Retention experiments were performed after
3 h of daunorubicin exposure by washing the cells three times
in ice-cold PBS then determining the intracellular dauno-
rubicin remaining after the indicated times of incubation.
Daunorubicin fluorescence wxas plotted after subtracting
background counts (0 time at 4°C) from all measurements.
[ estern blot anal!sis
Cellular l-sates for topoisomerase II immunoblots were
prepared as previously described (Kaufmann et al.. 1987).
Cellular proteins wxere separated on 5- 15100 gradient sodium
dodecyl sulphate (SDS)-polyacrylamide gels and transferred
to nitrocellulose by electroblotting. The membranes were
blocked in TSM buffer (0.15 m sodium chloride. 10mm
Tris-HCI pH 7.4. 500 skimmed milk). The blots were hyb-
ridised with a 1:500 dilution of rabbit antiserum against
gel-purified topoisomerase II in TSM buffer overnight at
room temperature. washed three times for 15 min each in TS
buffer (0.15 M sodium chloride. 10 mm Tris-HCl pH 7.4)
with 0.05O NP-40. then incubated for 90 min at roomtemperature with 'MI-labelled goat anti-rabbit IgG (Amer-
sham) in TSM buffer. The membranes were washed five times
as before then developed for 6-24 h.
Western blotting for MRP was performed using detergent-
solubilised membrane proteins as previously described (Chen
et al., 1990). The antiserum used was termed anti-MRP.6KQ
by Dr N Krishnamachary, Kansas State University, and was
generated against a peptide corresponding to MRP amino
acids 246-260. The peptide had been conjugated to keyhole
limpet haemocyanin. and the conjugate used to immunise
New Zealand White rabbits (Krishnamachary and Center,
1993). Electrophoresis was performed using 50 fig of mem-
brane protein per lane. and immunoblotting was performed
with a 1:100 dilution of the antipeptide antisera. The blots
were developed using a chemiluminescent detection system
(ECL Kit. Amersham).
Reverse transcription PCR assa} jys
One microgram of total RNA from each cell line, isolated
using an RNA-STAT-60 kit (Tel-Test 'B'. Fnrendswood, TX.
USA). was reverse transcribed in 20 gil of RT buffer (10 mM
Tris-HCl pH 8.0, 50mM potassium chloride, 0.1% Triton
X-100. 5 mM magnesium chloride, 250 jiM each of dATP.
dGTP. dCTP. dTTP). containing 20 units of RNasin and 10
units of AML reverse transcriptase (both from Promega).
500 ng of specific pnrmers and 2 jig of yeast tRNA. Following
incubation at 42'C for 45 min, the mixture was heated to
99'C for Smin, then cooled to 4'C. The resulting cDNA
mixture was serially diluted in RT buffer. In each dilution,
the target sequences were amplified for 30 cycles by the
polymerase chain reaction with specific primers for each
gene, using 1.25 units of Taq DNA polymerase. The primers
used were : mdrl, 5'-primer nt 2322-2346, 3'-primer nt
2512-2536: MRP, 5'-primer nt 3898-3914, 3'-primer nt
4454-4471; n-microglobulin, 5'-primer nt 1552-1571, 3'-
primer nt 2252-2262 and nt 3207-3215 (Noonan and
Roninson, 1991). Ten microlitres of the reaction products
was separated on a 2% agarose gel in Tris-borate-EDTA
buffer. The PCR reaction product bands were visualised by
ethidium bromide staining.
Northern blot analysis
A 1 kb fragment from the 3' region of MRP cDNA cloned
into an EcoRI site in pGEM-3Zf(+), was obtained from Dr
S Cole. RNA was prepared from cells using the RNA-STAT-
60 kit. The cDNA clone, which was termed pmrp 10.1, was
used for labelling by random priming with [_-32P]dCTP
(Prime-a-Gene labelling system, Promega) and probing of
Northern blots. Twenty micrograms of total RNA was
separated on a 1.2% agarose gel in formaldehyde 4-
morpholinepropanesulphonic acid buffer. After transfer onto
Immobilon-N polyvinylidene difluoride membranes (Mil-
lipore, Bedford, MA. USA), the membrane was prehyb-
ridised overnight and hybridised at 42°C for 20 h with the
labelled MRP probe in 50% formamide. After washing, the
membrane was exposed to X-ray film for 4-16 h at - 70°C
with intensifying screens. To estimate variation in RNA
loading of the gel, the blots were stripped and rehybridised
with a 3-P-labelled cDNA probe from the 3' region of mouse
fractin (Tokunaga et al., 1986). Relative levels of MRP and
fractin mRNAs were determined by densitometry.
Southern blot analivsis
Isolation of genomic DNA. agarose gel electrophoresis and
DNA blot analysis followed standard procedures. Ten mic-
rograms of genomic DNA from each line was digested with
EcoRI and BamHI and electrophoresed through a 0.8%
agarose gel. After blotting onto a nitrocellulose membrane,
prehybridisation was carried out for 4 h at 42°C in 50%
formamide, 5 x standard saline phosphate-EDTA
(1 x = 3 M sodium chloride, 0.2 M sodium dihydrogen phos-
phate, 0.02 M EDTA, pH 7.4), 0.5% SDS. 4 x Denhardt's
E- re wi MR omer
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and herring testes DNA (100 jlgml-'). The blot was then
hybnrdised for 20 h at 42°C with the pmrp 10.1 probe and
labelled by random priming with [c-32P]dCTP as described
above. The blot was exposed to film and densitometry was
carred out as before. The 3"P-labelled MRP bands were also
quantified on a Betascope 603 blot analyser (Betagen, Wal-
tham. MA. USA).
Results
Cell line characteristics
The UMCC-1 VP subline had a doubling time of 48 h and
grew as loosely aggregated floating spheroids. The parental
UMCC-1 line had a similar doubling time, but grew with a
mixture of floating colonies and surface-adherent cells. The
NCI-H1514 and NCI-HI514 VP sublines each had doubling
times of approximately 60 h. The drug-resistant NCI-H1514
VP subline grew in less tightly compacted spheroid colonies
than did the parental line.
Drug resistance pattern
The NCI-H1514 and UMCC-1 parental cell lines had com-
parable sensitivity to antineoplastic drugs, although they
were derived from untreated and relapsed SCLC patients
respectively (Tables I and II). The UMCC-1 VP subline was
approximately 20-fold resistant to etoposide. relative to the
UMCC-1 parent line, but also more than 10-fold resistant to
doxorubicin, vincristine and actinomycin D (Table I). The
NCI-HI514,VP subline was approximately 10-fold resistant
to etoposide, relative to the parent line, but only 3-fold
resistant to doxorubicin and not detectably resistant to
actinomycin D or vincristine (Table II). The UMCC-1 VP
cell line was also found to have no cross-resistance to taxol
or thiotepa, and only 2-fold resistance to idarubicin, mel-
phalan and cisplatin, relative to the UMCC-1 line (Table I).
Drug accumulation and efflux
The UMCC-1,,VP subline had markedly reduced accumula-
tion of etoposide compared with the sensitive parental line
Table I SensitiVitv of UMCC-1 and
drugs
UMCC-I VP to c-totoxic
L-MCC-I LMAfCC-J VP
Drug IC" ( W)± s.e. IC" ( m)± s.e. Fold
Etoposide 0.6153 ± 0.085 13.822 ± 1.83 22.5
Doxorubicin 0.0194 ± 0.0022 0.2452 ± 0.02 12.9
Vincristine 0.00074 ± 0.000065 0.0081 ± 0.0012 10.9
Actinomycin D 0.9349 ± 0.046 9.5252 ± 1.04 10.2
Taxol 0.0097 ± 0.0021 0.0073 ± 0.0016 0.78
Melphalan 14.1 ± 2.4 33.5 ± 6.9 2.4
Idarubicin 0.11 ± 0.038 0.22 ± 0.08 2.0
Cisplatin 2.5 ± 0.12 4.9±0.017 1.95
Thiotepa 79.1 ± 17.3 82.6 ± 28.4 1.04
IC50 concentrations were determined by the MTT assay as described
in Materials and methods. Values represent the means ± s.e. of
quadruplicate determinations in a representative experiment.
Table n Sensitivity of NCI-H1514 and NCI-H1514 VP to cytotoxic
drugs
NCI-HJ514 NCI-HJ514 VP
Drug IC, (;L}w) ± s.e. IC" (;im. ± s.e. Fold
Etoposide 0.7326 0.091 9.8828 ± 1.52 13.5
Doxorubicin 0.0382 ± 0.0048 0.1273 ± 0.012 3.3
Vincristine 0.0012 ± 0.00015 0.0021 ± 0.00022 1.75
Actinomycin D 1.2001 0.10 1.2839 ± 0.10 1.06
IC50 concentrations were determined by the MTT assay as described
in Materials and methods. Values represent the means ± s.e. of
quadruplicate determinations in a representative experiment.
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(Figure 1). The NCI-Hl514 VP subline, in contrast, had
levels of intracellular etoposide similar to the parental cells
(data not shown). The UMCC-l/VP subline had a small but
reproducible reduction in daunorubicin accumulation relative
to the parental cells and had decreased retention of intracel-
lular anthracycine. although the initial slopes of drug efflux
from UMCC-1 and UMCC-1,VP were similar (Figure 2).
The decreased retention of daunorubicin in the UMCC-l VP
subline relative to UMCC-1 was particularly marked after
overnight incubation of the cells in drug-free medium.
Topoisomerase II expression
The resistance of NCI-H1514NVP to doxorubicin and
etoposide but not vincristine or actinomycin D suggested an
alteration in DNA topoisomerase II activity in this resistant
subline. Immunoblot analysis with antisera against topoiso-
merase II, however, demonstrated only a modest difference in
topoisomerase II protein levels between each of the two
resistant sublines and their corrresponding drug-sensitive
parental lines (Figure 3). Densitometric analysis revealed that
UMCC-lYVP and NCI-H1514 VP each had an approximate
50% reduction in immunoreactive topoisomerase II content
relative to the parental line. Preliminary studies of to-
poisomerase II activity from nuclear extracts of NCI-HI514
VP and UMCC-l VP do not reveal significant differences in
either relaxation of supercoiled DNA or etoposide-mediated
DNA cleavage compared with the parental lines (data not
shown).
P-glvcoprotein and MRP expression
The relative resistance of UMCC-1 VP to vincristine and
actinomycin D. as well as to doxorubicin and etoposide,
suggested that cells of the resistant subline might overexpress
mdrl. However, reverse transcription PCR assays demon-
strated that neither UMCC-l VP nor NCI-HI514/VP overex-
pressed mdrl mRNA (Figure 4). The predicted 190 bp band
was seen in the HL-60 Vinc subline, which overexpresses
mdrl, and with an mdrl cRNA control. A control .,-
microglobulin 120 bp band was demonstrable in each lane of
a parallel PCR assay, indicating that the lack ofmdrl expres-
sion in the lung cancer cells was not due to degraded RNA
(Figure 4).
Reverse transcription PCR assays using MRP primers
demonstrated that the UMCC-1 VP subline strongly ex-
12
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pressed a predicted 575 bp MRP band to a level similar to
that of the control HL-60/ADR subline, which is known to
have amplification and overexpression of the MRP gene
(Figure 5) (Krishnamachary and Center, 1993). Under the
conditions used, no MRP expression was detectable in the
parental UMCC-1 lane or in the NCI-H1514 and NCI-
H1514/VP lanes, although control P2-microglobulin bands
C
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Fgwe 2 Daunorubicin accumulation and retention in UMCC-l
(0) and UMCC-1 VP (0) cells. Cells were exposed to
daunorubicin (1 jigmlP ) for various times and daunorubicin
intracellular content was determined by direct fluorescence of the
drug by flow cytometry. Retention of daunorubicin after a 3 h
accumulation was determined by washing the cells free of extra-
cellular drug and culturing in drug-free medium. The remaining
daunorubicin fluorescence was measured by flow cytometry at the
times indicated.
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Fig_e 3 Western blotting for DNA topoisomerase II with ex-
tracts from leukaemia and lung cancer cells. The cellular lysates
were separated on a 5-15% gradient SDS/polyacrylamide gel
and transferred onto a nitrocellulose membrane. The membrane
was incubated with a polyclonal rabbit antisera against
topoisomerase II, followed by "MI-labelled goat anti-rabbit IgG.
Lane 1, HL-60; lane 2, NCI-H1514; lane 3, NCI-H1514 VP; lane
4, UMCC-I; lane 5, UMCC-1 VP.
rnsct i3- Microgiobulir
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Fgre I Etoposide accumulation in UMCC-1 (0) and UMCC-
I VP (0) cells. Exponentially growing cells were incubated with
0.5piCi ml (900 mCi mmol- ') [3H}etoposide plus 10 IM un-
labelled etoposide at 37TC. At the indicated time points the cells
were washed, and radioactivity was determined by liquid scintilla-
tion counting. The results shown are the means ± s.e. from two
separate experiments.
Figure 4 Quantitative PCR assay for mdrl and A-microglobulin.
Total RNA was isolated from each cell line and reverse trans-
crnbed. Each resulting cDNA was amplified with primer pairs for
mdrl or -n-microglobulin. Ten microlitres of each amplified reac-
tion mixture was separated on a 2% agarose gel in Tris-borate-
EDTA. The bands were visualised by ethidium bromide staining
and photographed, with an expected 190 bp mdrl PCR product
and an expected 120 bp A-microglobuhin PCR product. Lane 1,
marker DNA; lane 2, no DNA added, lane 3, HL-60; lane 4,
HL-60Vinc; lane 5, mdrl cRNA; lane 6, NCI-H1514; lane 7,
NCI-H1514,/VP; lane 8, UMCC-1; lane 9, UMCC-1,VP; lane 10,
HL-60; lane 11, HL-60/Vinc; lane 12, NCI-H1514; lane 13, NCI-
H1514 VP; lane 14, UMCC-1; lane 15, UMCC-1 VP.
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190 bD- 120 Dcwere readily detectable in a PCR reaction using RNA from
these lines (Figure 5).
The 575 bp PCR product was subsequently cut out of the
gel and purified by phenol-chloroform extraction and
ethanol precipitation. The DNA was sequenced on an
Applied Biosystems automated sequencer. using the original
PCR primer sequences as templates. DNA sequence analysis
revealed that the PCR product sequence was consistent with
authentic MRP (data not shown).
Relative overexpression of MRP in the UMCC-1IVP sub-
line. suggested by reverse transcription PCR assays, was
confirmed by Northern blotting experiments with an MRP
cDNA probe (Figure 6). A marked increase in the 6.7 kb
MRP RNA band, relative to the parental UMCC-1 line, was
indicated by radioautography after a 4 h film exposure. No
relative overexpression of MRP in the NCI-H1514,VP sub-
line was demonstrated by Northern blotting.
Immunoblotting of the UMCC-1 and UMCC-1 VP sub-
lines with antisera against an MRP peptide conjugate
revealed the expected 195 kDa band in the resistant subline
(Figure 7). Only a faint 195 kDa band was noted in the lane
containing membrane proteins from the parental UMCC-1
line.
Amplification of the MRP gene in the UMCC-l VP sub-
line was demonstrable by Southern analysis (Figure 8). Beta-
scope quantitation of 2P emissions from bands on the MRP
Esde re wit k omerp
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Southern blot demonstrated an 1 -fold increase in counts
from the UMCC-1 VP subline relative to the parental
UMCC-1 line.
1 2
200 kDa-
Figure 7 Western blotting for MRP expression in SCLC cell
sublines. Fifty micrograms of detergent-solubilised membrane
proteins from each line was separated by electrophoresis on
8-14% polyacrylamide gels and transferred to nitrocellulose. The
blots were incubated with a 1:100 dilution of rabbit anti-MRP
peptide antisera, and developed with a chemiluminescent detec-
tion system. Lane 1. UMCC-1; lane 2. UMCC-1 VP.
Figre 5 Quantitative PCR assay for MRP in leukaemia and
lung cancer cells. Total RNA was isolated from each cell line and
reverse transcribed. Each resulting cDNA was amplified with
primer pairs for MRP or P-microglobulin. Ten microlitres of
each amplified reaction mi'xture was separated on a 2% agarose
gel in Tris-borate-EDTA. The 575 bp MRP bands and 120 bp
P-microglobulin bands were visualised by ethidium bromide
staining and photographed. Lane 1. HL-60; lane 2, HL-60 ADR:
lane 3. UMCC-l VP: lane 4. UMCC-1; lane 5, NCI-H1514 VP;
lane 6, NCI-H1514.
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Fgre 6 Northern blotting for MRP expression in SCLC cell
lines. Total cellular RNA (20 jig) from each cell line was
separated on a 1.2% agarose gel, transferred to a PVDF mem-
brane and hybridised with the radiolabelled pmrp 10.1 probe.
The blot was later stripped and rehybridised with a control
A-actin probe. Lane 1. UMCC-1 VP; lane 2. UMCC-1; lane 3,
NCI-HI514 VP; lane 4, NCI-H1514.
Fiure 8 Southern blot analysis of SCLC cell lines with an MRP
probe. Ten micrograms of DNA from each line was digested with
EcoRI and BamHI, electrophoresed on a 0.8% agarose gel. trans-
ferred to a nitrocellulose filter and hybridised with the labelled
pmrp 10.1 probe. Lane 1. NCI-H1514; lane 2. NCI-H1514 VP:
lane 3. UMCC-1; lane 4. UMCC-1 VP.
1 2 3 4
- 9.2 kb
- 6.6 kb
- 4.4 kb
- 2.6 kb
- 1.6 kbEtopMide resistance with LA Doyle et al
Modulation ofdrug resistance in l'MCC-J VP cells
Verapamil. at a 1O IM concentration. produced a 4-fold sen-
sitisation of UMCC-1 VP cells to etoposide in MTT assays
(Table III). Cyclosporin A. at a 2 JiM concentration. caused a
2-fold sensitisation to etoposide in UMCC-1 VP cells (Table
III). Exposure of UMCC-1 VP cells to a 5 tuM concentration
of cyclosporin A for 72 h in the MTT assays resulted in
unacceptable toxicity by the modulator (data not shown).
Preincubation of UMCC-1 VP cells for 24 h by either 25 or
50 gM BSO caused a 2.4-fold sensitisation of the cells to
etoposide and a 6.3-fold sensitisation to daunorubicin (Table
III).
Discion
We have demonstrated MRP gene amplification and overex-
pression in a human SCLC subline made resistant in vitro to
etoposide. The resistant subline UMCC-L VP demonstrates
resistance to other cytotoxic agents and decreased etoposide
accumulation with no detectable expression of mdrl. The
unaltered growth rate of the UMCC-1LVP cells, along with
their vincristine resistance and the initial topoisomerase II
characterisation, suggests that MRP overexpression may be
the dominant mechanism of MDR in this subline. There is
no explanation yet for the 10-fold resistance to etoposide
demonstrated by the other subline NCI-H1514 VP. This sub-
line has undetectable mdrl or MRP expression and unaltered
etoposide levels. While the immunoreactive topoisomerase II
protein was only reduced by 50% in NCI-H1514/VP. relative
to the parent line, the pattern of drug resistance is consistent
with an altered topoisomerase. Further topoisomerase II
functional assays and sequence analysis for mutations are
currently being conducted in the NCI-H1514/VP subline.
MRP amplification and overexpression has been noted in
doxorubicin-resistant lung cancer cell lines such as the SCLC
line GLC4 Adr and the non-small-cell lung cancer lines
COR-L23 R and MOR 0.4R (Barrand et al.. 1993. 1994:
Zaman et al.. 1993). MRP overexpression has also been
demonstrated in anthracycine-selected leukaemia and
fibrosarcoma sublines (Krishnamachary and Center. 1993:
Slovak et al., 1993).
Antisera derived against synthetic MRP proteins demon-
strate that the MRP protein is 195 kDa on immunoblots and
enriched in membrane fractions (Krishnamachary and
Center. 1993). Treatment of HL60/ADR cells wtih tunica-
mycin results in the appearance of a 165 kDa band reactive
with the antipeptide serum (Krishnamachary and Center,
1993). We have used antipeptide antisera, obtained from Dr
M Center, to demonstrate MRP protein in UMCC-I VP
membrane proteins by immunoblotting of one-dimensional
and two-dimensional polyacrylamide gels and to reproduce
the tunicamycin results in our cell line (manuscript in
preparation).
The role of MRP in cellular drug accumulation is still
undefined. Cole et al. (1992) originally reported little change
in doxorubicin accumulation in the H69AR subline relative
to the parental cells, but Coley et al. (1991) have found
decreased levels of daunorubicin and vincnrstine in the MRP-
overexpressing line COR-L23 R. relative to its parent line,
after an initial delay of 30-60 min. The MRP-overexpressing
cell lines GLC4 Adr and HL-60 Adr have also been found to
have decreased anthracycline accumulation relative to the
parental drug-sensitive cell lines (Marquardt and Center,
1992: Versantvoort et al.. 1992). These results parallel our
findings with the UMCC-1 VP subline. in which decreased
daunorubicin accumulation and retention is most evident at
later time points, suggesting a relatively slower efflux process.
Most recently, MRP transfectants of HeLa cells have been
demonstrated to have a modest decrease in vincristine
accumulation (Grant et al.. 1994b).
The UMCC-1 VP subline appears to demonstrate a greater
relative decrease in etoposide accumulation than in the
accumulation or retention of daunorubicin. Since the cells
were selected in etoposide. mechanisms other than MRP may
effect the transport of etoposide into this subline. Alterna-
tively, since there is less non-specific membrane binding and
DNA intercalation of epipodophyllotoxins than anthracyc-
lines, the contribution of MRP to intracellular drug
accumulation may be better seen with the former agents (Liu.
1989). Studies of etoposide accumulation in MRP-transfected
cells will be useful in determining the role of MRP in the
transport of this drug. Further experiments. using lower con-
centrations of anthracyclines. might also demonstrate greater
differences in drug accumulation in MRP-overexpressing
cells.
We have demonstrated a 4-fold sensitisation of UMCC-1
VP cells to etoposide by concomitant incubation with 10 AM
verapamil. These findings are similar to the 4-fold sensitisa-
tion to vincnrstine and 9-fold sensitisation to daunorubicin by
verapamil reported in L231R cells, which overexpress MRP
(Barrand et al., 1993). We could not demonstrate sensitisa-
tion of UMCC-1lVP cells to etoposide by non-toxic concen-
trations of cyclosporin A. Cyclosporin A has been previously
demonstrated to have little effect on sensitisation to
daunorubicin or doxorubicin in the MRP-overexpressing cell
lines GLC4-Adr and HL60 AR (Gollapudi et al.. 1992; van
der Graaf et al.. 1994).
We have demonstrated partial reversal of etoposide and
daunorubicin resistance in UMCC-1 VP cells by pretreatment
of the cells with BSO. MRP has been recently demonstrated
to be an ATP-dependent glutathione S-conjugate transporter
(Jedlitschky et al.. 1994; Muller et al.. 1994). The association
between glutathione depletion by BSO and chemoresensitisa-
tion to daunorubicin or etoposide is unclear, because these
drugs are not known to be conjugated to glutathione. How-
ever. BSO pretreatment has been demonstrated to increase
anthracycline accumulation and cytotoxicity in several cell
lines which overexpress MRP (Lutzky et al.. 1989: Meijer et
al., 1991; Gollapudi et al.. 1992: Longhurst et al.. 1994).
While most cancer cell lines overexpressing MRP have
been selected with anthracyclines. MRP overexpression has
been recently reported in an MCF-7 breast cancer subline
Table III Effects ofcyclosporin A. verapamil and BSO on sensitivity ofUMCC-I VP cells
to daunorubicin and etoposide
Modifier
None Cvclosporin A Verapamil BSO
Etoposide
lC,O 28.3± 11.6 13.1 ±2.4 7.3±2.6 11.8±2.0
Sensitisation ratio 1.0 2.2 3.9 2.4
Daunorubicin
1CfO 0.300 ± 0.55 NT NT 0.048 ± 0.0078
Sensitisation ratio 1.0 6.3
ICy, values are shown as the mean ± s.e. calculated from data obtained in two
experiments. each based on determinations from four wells. Sensitisation ratios were
calculated as IC.0 without modifier IC50 with modifier. Cyclosporin A was 2;LM and
verapamil was 101jM. Cells were pretreated with 25.lM BSO for 24h before adding
etoDoside or daunorubicin.-id ms wi P m S
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selected in etoposide (Schneider et al.. 1994). This subline
also demonstrated decreased accumulation of etoposide
relative to the parent cells in the absence of detectable mdrl
expression. The expression of MRP by the UMCC-1 VP
subline appears to be greater than that of the MCF-7 VP line
reported, since Northern blotting experiments easily detected
MRP in UMCC-1 VP after a 4 h film exposure, while a 14
day exposure was used for the MCF-7 VP subline. While
these two sublines have approximately the same relative resis-
tance to etoposide and doxorubicin. the UMCC-1 VP subline
was more resistant to vincristine and had a greater apparent
decrease in etoposide accumulation. The differences in MDR
phenotype between these two etoposide-resistant sublines
may be related to concomitant changes in topoisomerase II
activity dunrng the drug selection process. The UMCC-1 VP
subline confirms that MRP gene amplification and overex-
pression can occur during etoposide selection of resistant
cells, and suggests that MRP overexpression may contribute
to the atypical multidrug resistance seen after etoposide-
based induction chemotherapy in bronchial malignancies.
Abbreviations: MDR, multidrug resistance: P-gp. P-glycoprotein;
MRP. multidrug resistance-associated protein: WT. wild type: PBS.
phosphate-buffered saline: SDS. sodium dodecyl sulphate: IC-%. drug
concentration that inhibits cell growth by 50% under the assay
conditions used: SCLC. small-ell lung cancer: MTT. 3-(4.5-
dimethylthiazol-2-yl)2.5-diphenyltetrazolium bromide: AML. acute
myelogenous leukaemia; BSO. buthionine sulphoximine.
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